New breakthroughs could help make multiple sclerosis history

Researchers are gaining a new level of understanding of multiple sclerosis (MS), which could lead to new treatments and approaches to controlling the chronic disease.

The new findings show that scientists are one step closer to understanding how antibodies in the blood stream break past the brain’s protective barrier to attack the optic nerves, spinal cord, and brain, causing the symptoms of neuromyelitis optica, a rare disease similar to MS.

Understanding how the antibodies bypass the protective blood-brain barrier could provide new approaches to treating the disease (Yukio Takeshita, MD, PhD, abstract 404.09).

A protein involved in blood clotting mightserve as an early detection method for MS before symptoms occur. Early detection of the disease could lead to more effective early treatments ( Katerina Akassoglou, PhD, abstract 404.11).

Low levels of a cholesterol protein correlate with the severity of a patient’s MS in both human patients and mouse models.

The finding suggests the protein, known to protect against inflammation, may protect against developing MS, and possibly even aid in the regeneration of damaged neurons. This research opens the door to cholesterol drugs as a possible new avenue for MS treatment (Lidia Gardner, PhD, abstract 404.01).

A type of immune system cell has been found to directly target and damage nerve cell axons, a hallmark of MS. This may reveal a target for new therapies (Brian Sauer, PhD, presentation 404.06).

While no treatments to rebuild cells damaged by MS currently exist, scientists have found that when exosomes – tiny, naturally occurring “nanovesicles” – are produced by dendritic cells and applied to the brain, they can deliver a mixture of proteins and RNAs that promote regeneration of protective myelin sheaths and guard against MS symptoms ( Richard Kraig , MD, PhD, presentation 812.02)

Source: Zee News

 


A Bio-Patch Regrows Bone inside the Body

Researchers from the University of Iowa have developed a remarkable new procedure for regenerating missing or damaged bone. It’s called a “bio patch” — and it works by sending bone-producing instructions directly into cells using microscopic particles embedded with DNA.

In experiments, the gene-encoding patch has already regrown bone fully enough to cover skull wounds in test animals. It has also stimulated new growth in human bone marrow stromal cells. Eventually, the patch could be used to repair birth defects involving missing bone around the head or face. It could also help dentists rebuild bone in areas which provides a concrete-like foundation for implants.

To create the bio patch, a research team led by Satheesh Elangovan delivered bone-producing instructions to existing bone cells inside a living body, which allowed those cell to produce the required proteins for more bone production. This was accomplished by using a piece of DNA that encodes for a platelet-derived growth factor called PDGF-B. Previous research relied on repeated applications from the outside, but they proved costly, intensive, and more difficult to replicate with any kind of consistency.

“We delivered the DNA to the cells, so that the cells produce the protein and that’s how the protein is generated to enhance bone regeneration,” explained Aliasger Salem in a statement. “If you deliver just the protein, you have keep delivering it with continuous injections to maintain the dose. With our method, you get local, sustained expression over a prolonged period of time without having to give continued doses of protein.” Salem is a professor in the College of Pharmacy and a co-corresponding author on the paper.

While performing the procedure, the researchers made a collagen scaffold in the actual shape and size of the bone defect. The patch, was loaded with synthetically created plasmids and outfitted with the genetic instructions for building bone did the rest, achieving complete regeneration that matched the shape of what should have been there. This was followed by inserting the scaffold onto the missing area. Four weeks is usually all that it took — growing 44-times more bone and soft tissue in the affected areas compared to just the scaffold alone.

“The delivery mechanism is the scaffold loaded with the plasmid,” Salem says. “When cells migrate into the scaffold, they meet with the plasmid, they take up the plasmid, and they get the encoding to start producing PDGF-B, which enhances bone regeneration.”

The researchers also note that the delivery system is nonviral, meaning that the plasmid is not likely to cause an undesired immune response, and that it’s easier to mass produce, which lowers the cost.

Source: Discovery news

 


Cow’s milk may harbour gastric cancer cure

A new research has indicated that a peptide fragment derived from cow’s milk, known as lactoferricin B25 (LFcinB25), exhibited potent anticancer capability against human stomach cancer cell cultures.

Wei-Jung Chen, PhD, of the Department of Biotechnology and Animal Science of National Ilan University, Taiwan Republic of China evaluated the effects of three peptide fragments derived from lactoferricin B, a peptide in milk that has antimicrobial properties.

Only one of the fragments, LFcinB25 reduced the survival of human AGS (Gastric Adenocarcinoma) cells in a dose-dependent and time-dependent manner.

Under a microscope the investigators could see that after an hour of exposure to the gastric cancer cells, LFcinB25 migrated to the cell membrane of the AGS cells, and within 24 hours the cancer cells had shrunken in size and lost their ability to adhere to surfaces.

In the early stages of exposure, LFcinB25 reduced cell viability through both apoptosis (programmed cell death) and autophagy (degradation and recycling of obsolete or damaged cell parts). At later stages, apoptosis appeared to dominate, possibly through caspase-dependent mechanisms, and autophagy waned.

The research also suggested a target, Beclin-1, which may enhance LFcinB25’s cytotoxic action. Beclin-1 is a protein in humans that plays a central role in autophagy, tumour growth, and degeneration of neurons.

“Optimization of LFcinB using various strategies to enhance further selectivity is expected to yield novel anticancer drugs with chemotherapeutic potential for the treatment of gastric cancer,” Dr. Chen said.

The study is published in the Journal of Dairy Science.

Source; deccan chronicle

 

Cow’s milk

lactoferricin B25

newswrap


Surgeon Wins Award For 95p Invention

Dr Hossien spent over six months developing his invention A heart surgeon at a Swansea hospital has won an award for an invention that cost him 95p to create. Morriston hospital doctor Abdull razak Hossien made his surgery training simulator out of a sweet tin. The portable device can be used anywhere and is now being manufactured for use around the world

Dr Hossien spent over six months developing his invention

A heart surgeon at a Swansea hospital has won an award for an invention that cost him 95p to create.

Morriston hospital doctor Abdullrazak Hossien made his surgery training simulator out of a sweet tin.

The portable device can be used anywhere and is now being manufactured for use around the world.

It is used in training for surgery of the aortic root, which carries blood from the left side of the heart to the arteries of the limbs and organs.

Dr Hossien created his training device for a competition run as part of the European Association for Cardiothoracic Surgery (EACTS) Conference 2013 in Vienna.

He said: “Thomas Edison said that to invent you need a good imagination and a pile of junk.

“I designed a portable trainer, which you can keep in your pocket. You can practise on the train, on an airplane, at home, wherever you are.

“I developed it from a sweet tin that can be fixed to a table, and created an aorta using synthetic material. It cost me around 95p.

“I accompanied this simulator with a multimedia DVD [with] guidelines that trainees can apply to any procedure on the aortic root. They can progress from the simplest procedure to the most complex as they develop.”

Dr Hossien said trainees using the simulator would be completely familiar with the procedures by the time they came to carry out supervised aortic root surgery on patients.

He added: “They will have mastered the procedure before they operate on the patient.”

Garage workshop

Dr Hossien said that at the same time “qualified surgeons and any doctor with an interest in the specialty can improve their skills”.

The prototype simulator was made from a sweet tin

For the EACTS award, candidates were challenged to create a low-tech training simulator for aortic root surgery.

These were judged by a panel of eight top surgeons from Europe and the USA.

Dr Hossien was eventually declared joint winner along with a candidate from Italy.

His simulator will be manufactured for worldwide use by award sponsor Ethicon, which develops innovative surgical products.

Dr Hossien turned the garage of his Swansea home into a workshop to develop the aortic root simulator.

“I spent six or seven months on it. I would forget to eat and to drink sometimes because I was thinking about it so much.

“I would like to thank my wife and daughter who supported me and gave me the time I needed to develop this.”

He is donating his share of the 3,000 euro (£2,600) first prize from the EACTS award to the Syrian humanitarian relief appeal.

Dr Hossien is senior clinical research fellow in the cardiothoracic department at Morriston Hospital.

Mr Saeed Ashraf, consultant cardiothoracic surgeon and honorary senior lecturer at Swansea University said: “Dr Hossien is a very talented academic surgeon with an excellent pair of surgical hands.”

Source: 24all news


Doctors discover new ligament in the human knee

The discovery explains why ACL-treated patients continued to experience a “pivot shift” of the knees

Two doctors at University Hospitals Leuven in Belgium have discovered a new ligament, the anterolateral ligament, which has been linked to anterior cruciate ligament, more commonly known as the ACL.

Building on work done by a French surgeon in 1879, Dr. Steven Claes and Dr. Johan Bellemans discovered the ligament in the front of the knee, and detailed their findings in the Journal of Anatomy.

Using macroscopic dissection techniques, the two doctors studied 41 cadaveric knees and found the ALL in all but one knee.

ACL tears are common in athletes playing sports with high demands on the knees, such as soccer, basketball and football.

Even after successful surgery, some patients with repaired ACLs continue to experience buckling of the knee during intense physical activity.

In the past, this “pivot shift” confused doctors, leading them to suspect that some part of the equation was unknown. With the discovery of the ALL, continued pivot shifts following ACL repair can be explained.

The discovery could signal a breakthrough in the treatment of ACL tears and further knowledge about the human body.

Source: UPI


Vietnam releases dengue-blocking mosquito

Nguyen Thi Yen rolls up the sleeves of her white lab coat and delicately slips her arms into a box covered by a sheath of mesh netting. Immediately, the feeding frenzy begins.

Hundreds of mosquitoes light on her thin forearms and swarm her manicured fingers. They spit, bite and suck until becoming drunk with blood, their bulging bellies glowing red. Yen laughs in delight while her so-called “pets” enjoy their lunch and prepare to mate.

The petite, grandmotherly entomologist _ nicknamed Dr. Dracula _ knows how crazy she must look to outsiders. But this is science, and these are very special bloodsuckers.

She smiles and nods at her red-hot arms, swollen and itchy after 10 minutes of feeding. She knows those nasty bites could reveal a way to greatly reduce one of the world’s most menacing infectious diseases.

All her mosquitoes have been intentionally infected with bacteria called Wolbachia, which essentially blocks them from getting dengue. And if they can’t get it, they can’t spread it to people.

New research suggests some 390 million people are infected with the virus each year, most of them in Asia. That’s about one in every 18 people on Earth, and more than three times higher than the World Health Organization’s previous estimates.

Known as “breakbone fever” because of the excruciating joint pain and hammer-pounding headaches it causes, the disease has no vaccine, cure or specific treatment. Most patients must simply suffer through days of raging fever, sweats and a bubbling rash. For those who develop a more serious form of illness, known as dengue hemorrhagic fever, internal bleeding, shock, organ failure and death can occur.

And it’s all caused by one bite from a female mosquito that’s transmitting the virus from another infected person.

So how can simple bacteria break this cycle? Wolbachia is commonly found in many insects, including fruit flies. But for reasons not fully understood, it is not carried naturally by certain mosquitoes, including the most common one that transmits dengue, the Aedes aegypti.

The germ has fascinated scientist Scott O’Neill his entire career. He started working with it about two decades ago at Yale University. But it wasn’t until 2008, after returning to his native Australia, that he had his eureka moment.

One of his research students figured out how to implant the bacteria into a mosquito so it could be passed on to future generations. The initial hope was that it would shorten the insect’s life. But soon, a hidden benefit was discovered: Wolbachia-infected mosquitoes not only died quicker but they also blocked dengue partially or entirely, sort of like a natural vaccine.

“The dengue virus couldn’t grow in the mosquito as well if the Wolbachia was present,” says O’Neill, dean of science at Monash University in Melbourne. “And if it can’t grow in the mosquito, it can’t be transmitted.”

But proving something in the lab is just the first step. O’Neill’s team needed to test how well the mosquitoes would perform in the wild. They conducted research in small communities in Australia, where dengue isn’t a problem, and the results were encouraging enough to create a buzz among scientists who have long been searching for new ways to fight the disease. After two and a half years, the Wolbachia-infected mosquitoes had overtaken the native populations and remained 95 percent dominant.

But how would it work in dengue-endemic areas of Southeast Asia? The disease swamps hospitals in the region every rainy season with thousands of sick patients, including many children, sometimes killing those who seek help too late.

The Australians tapped 58-year-old Yen at Vietnam’s National Institute of Hygiene and Epidemiology, where she’s worked for the past 35 years. Their plan was to test the Wolbachia mosquitoes on a small island off the country’s central coast this year, with another release expected next year in Indonesia.

Just getting the mosquitoes to Tri Nguyen Island was an adventure. Thousands of tiny black eggs laid on strips of paper inside feeding boxes had to be hand-carried inside coolers on weekly flights from Hanoi, where Yen normally works, to Nha Trang, a resort city near the island. The eggs had to be kept at just the right temperature and moisture. The mosquitoes were hatched in another lab before finally being transported by boat.

Yen insisted on medical checks for all volunteer feeders to ensure they weren’t sickening her mosquitoes. She deemed vegetarian blood too weak and banned anyone recently on antibiotics, which could kill the Wolbachia.

“When I’m sleeping, I’m always thinking about them,” Yen says, hunkered over a petri dish filled with dozens of squiggling mosquito pupae. “I’m always worried about temperature and food. I take care of them same-same like baby. If they are healthy, we are happy. If they are not, we are sad.”

Recently, there have been several promising new attempts to control dengue. A vaccine trial in Thailand didn’t work as well as hoped, proving only 30 percent effective overall, but it provided higher coverage for three of the four virus strains. More vaccines are in the pipeline. Other science involves releasing genetically modified “sterile” male mosquitoes that produce no offspring, or young that die before reaching maturity, to decrease populations.

Wolbachia could end up being used in combination with these and other methods, including mosquito traps and insecticide-treated materials.

“I’ve been working with this disease now for 40-something years, and we have failed miserably,” says Duane Gubler, a dengue expert at the Duke-NUS Graduate Medical School in Singapore who is not involved with the Wolbachia research.

“We are now coming into a very exciting period where I think we’ll be able to control the disease. I really do.”

Wolbachia also blocks other mosquito-borne diseases such as yellow fever and chikungunya, O’Neill says. Similar research is being conducted for malaria, though that’s trickier because the disease is carried by several different types of mosquitoes.

It’s unclear why mosquitoes that transmit dengue do not naturally get Wolbachia, which is found in up to 70 percent of insects in the wild. But O’Neill doesn’t believe that purposefully infecting mosquitoes will negatively impact ecosystems. He says the key to overcoming skepticism is to be transparent with research while providing independent risk analyses and publishing findings in high-caliber scientific journals.

“I think, intuitively, it makes sense that it’s unlikely to have a major consequence of introducing Wolbachia into one more species,” O’Neill says, adding that none of his work is for profit. “It’s already in millions already.”

Dengue typically comes in cycles, hitting some areas harder in different years. People remain susceptible to the other strains after being infected with one, and it is largely an urban disease with mosquitoes breeding in stagnant water.

Laos and Singapore have experienced their worst outbreaks in recent history this season. Thailand has also struggled with a large number of patients. Cases have also been reported in recent years outside tropical regions, including in the U.S. and Europe.

Vietnam has logged lower numbers this year overall, but the country’s highest dengue rate is in the province where Yen is conducting her work.

At the area’s main hospital in Nha Trang, Dr. Nguyen Dong, director of infectious diseases, says 75 of the 86 patients crammed into the open-air ward are infected with the virus.

Before jabbing his fingers into the stomach of one seriously ill patient to check for pain, he talks about how the dengue season has become much longer in recent years. And despite the government’s increased education campaigns and resources, the disease continues to overwhelm the hospital.

If the experiment going on just a short boat ride away from the hospital is successful, it eventually will be expanded across the city and the entire province.

The 3,500 people on Tri Nguyen island grew accustomed to what would be a bizarre scene almost anywhere else: For five months, community workers went house-to-house in the raging heat, releasing cups of newborn mosquitoes.

And the residents were happy to have them.

“We do not kill the mosquitoes. We let them bite,” says fisherman Tran To. “The Wolbachia living in the house is like a doctor in the house. They may bite, but they stop dengue.”

Specimens collected from traps are taken back to the lab for analysis to determine how well Wolbachia mosquitoes are infiltrating the native population.

The strain of bacteria used on the island blocks dengue 100 percent, but it’s also the hardest to sustain. At one point, 90 percent of the mosquitoes were infected, but the rate dropped to about 65 percent after the last batch was released in early September. A similar decrease occurred in Australia as well, and scientists switched to other Wolbachia strains that thrive better in the wild but have lesser dengue-blocking abilities.

The job is sure to keep Yen busy in her little mosquito lab, complete with doors covered by long overlapping netting.

And while she professes to adore these pests nurtured by her own blood, she has a much stronger motivation for working with them: Dengue nearly claimed her own life many years ago, and her career has been devoted to sparing others the same fate.

“I love them,” she says, “when I need them.”

Source: postbulletin

 


New algorithm ‘boosts accuracy’ of physical activity apps

There are many cell phone apps that track your physical activity. These are useful, not only for your own sense of achievement, but also for doctors who look to these apps to track a patient’s movement and develop tailored treatments. Now, researchers have created a way to make these apps even more accurate.

 A team from Northwestern University in Chicago and Evanston say that previous research surrounding physical activity apps has shown that the majority of people who use them carry their cell phones in a bag, purse or pocket, or they attach it to a belt.

But the researchers note that the location of the phone can have a significant impact on how well the app can pick up a person’s movement.

Therefore, they have created a computer algorithm that can be used in conjunction with a physical activity app that is able to “predict” the location of a mobile phone throughout the day with “near perfect accuracy.”

“Most women carry their phones in a purse. Some people carry theirs on their belt or in their hand. We may change where we carry our phone throughout the day as well,” says first author Stephen Antos, of the McCormick School of Engineering and Applied Science at Northwestern University.

“We wanted to solve this problem and find a way to make these trackers as accurate as possible, no matter where you carry your phone.”

Algorithm ‘accurately detects second-by-second activity’

To create the algorithm, researchers recruited 12 healthy participants who were required to carry out a series of physical activities, including walking, sitting and standing.

During these activities, the participants carried smart phones in different locations – in their purse, backpack, belt, hand or pocket. This same method was also used on two people who had Parkinson’s disease.

The data from this experiment was then used to “train” a computer algorithm to predict where a person is carrying their cell phone, and from this, it was able to successfully detect “second-by-second” physical activity.

Commenting on the findings, published in the Journal of Neuroscience Methods, principal investigator Konrad Kording, of the Northwestern University Feinburg School of Medicine, says:

“While it remains true that smart phone activity trackers are the most accurate when the phone is placed in the pocket or on a belt, with this algorithm we can provide an estimate of error associated with other locations where the phone is carried.”

The researchers note that this algorithm can be applied to patient populations without hesitation, and Kording believes that in the future, smart phone apps will play a major part in helping us to manage our health.

“I believe we will have apps running on smart phones that will know exactly what we’re doing activity-wise and will warn us of diseases before we even know that we have those diseases,” he says.

“In the future, phones will have a major role in motivating people toward behavior that is good for their health.”

Source: Medical news today


Implantable sensor may monitor Glucose levels

In a paper published in the journal Nature Nanotechnology, scientists describe a newly developed sensor that is able to monitor nitric oxide in living animals and could potentially become a valuable asset to diabetic patients in the future.

 Nitric oxide is considered to be one of the most important signaling molecules in living cells, but in many cancerous cells levels are perturbed. Scientists have needed a new tool to help measure this molecule in the body and in real time.

The new sensor can be implanted under the skin and used to monitor inflammation, which is a process that produces nitric oxide. These sensors can also be adapted to detect other molecules, such as monitoring glucose or insulin levels in diabetic patients.

“So far we have only looked at the liver, but we do see that it stays in the bloodstream and goes to kidneys. Potentially we could study all different areas of the body with this injectable nanoparticle,” Nicole Iverson, who led the study, said in a statement.

Researchers have previously found that carbon nanotubes can detect nitric oxide if the tubes are wrapped in DNA with a particular sequence. Scientists in the latest study were able to modify the nanotubes to create two different types of sensors, including one that can be injected into the bloodstream for short-term monitoring and one that is able to be implanted under the skin for long-term.

Iverson attached a biocompatible polymer that inhibits particle-clumping in the bloodstream in order to make the particles injectable. The researcher found that when injected into mice, the particles flow through the lungs and heart without causing any damage.

The longer-term sensor consists of nanotubes embedded in a gel made from alginate. When this gel is implanted under the skin of the mice, it stays in place and remains functional for 400 days. This sensor could be used to monitor cancer or other inflammatory diseases, or detect immune reactions in patients with artificial hips or other implanted devices.

James Tour, a professor of chemistry at Rice University’s Smalley Institute for Nanoscale Science and Technology, pointed out that the new sensors merge the fields of chemistry, polymers, nanomaterials, biology, medicine, and optics.

“The selectivity and sensitivity are indeed impressive,” Tour, who was not a part of the study, said in a statement.

The team is now working on adapting the technology to help detect glucose by wrapping different molecules around the nanotubes. Diabetic patients have to prick their fingers multiple times a day to take blood glucose readings. However, if Iverson and colleagues are able to modify this sensor then it would not only offer real-time glucose monitoring, but it could also provide relief from the burden of constantly pricking one’s finger.

“The current thinking is that every part of the closed-loop system is in place except for an accurate and stable sensor. There is considerable opportunity to improve upon devices that are now on the market so that a complete system can be realized,” Michael Strano, the Carbon P. Dubbs Professor of Chemical Engineering at MIT, said in a statement.

Source: redorbit


Hair regeneration method uses patient’s own cells to grow new hair

Researchers at Columbia University Medical Center (CUMC) have devised a hair restoration method that can generate new human hair growth, rather than simply redistribute hair from one part of the scalp to another. The approach could significantly expand the use of hair transplantation to women with hair loss, who tend to have insufficient donor hair, as well as to men in early stages of baldness. The study was published today in the online edition of the Proceedings of the National Academy of Sciences (PNAS).

“About 90 percent of women with hair loss are not strong candidates for hair transplantation surgery because of insufficient donor hair,” said co-study leader Angela M. Christiano, PhD, the Richard and Mildred Rhodebeck Professor of Dermatology and professor of genetics & development. “This method offers the possibility of inducing large numbers of hair follicles or rejuvenating existing hair follicles, starting with cells grown from just a few hundred donor hairs. It could make hair transplantation available to individuals with a limited number of follicles, including those with female-pattern hair loss, scarring alopecia, and hair loss due to burns.”

According to Dr. Christiano, such patients gain little benefit from existing hair-loss medications, which tend to slow the rate of hair loss but usually do not stimulate robust new hair growth.

“Dermal papilla cells give rise to hair follicles, and the notion of cloning hair follicles using inductive dermal papilla cells has been around for 40 years or so,” said co-study leader Colin Jahoda, PhD, professor of stem cell sciences at Durham University, England, and co-director of North East England Stem Cell Institute, who is one of the early founders of the field.  “However, once the dermal papilla cells are put into conventional, two-dimensional tissue culture, they revert to basic skin cells and lose their ability to produce hair follicles.  So we were faced with a Catch-22: how to expand a sufficiently large number of cells for hair regeneration while retaining their inductive properties.”

The researchers found a clue to overcoming this barrier in their observations of rodent hair.  Rodent papillae can be easily harvested, expanded, and successfully transplanted back into rodent skin, a method pioneered by Dr. Jahoda several years ago. The main reason that rodent hair is readily transplantable, the researchers suspected, is that their dermal papillae (unlike human papillae) tend to spontaneously aggregate, or form clumps, in tissue culture. The team reasoned that these aggregations must create their own extracellular environment, which allows the papillae to interact and release signals that ultimately reprogram the recipient skin to grow new follicles.

“This suggested that if we cultured human papillae in such a way as to encourage them to aggregate the way rodent cells do spontaneously, it could create the conditions needed to induce hair growth in human skin,” said first author Claire A. Higgins, PhD, associate research scientist.

To test their hypothesis, the researchers harvested dermal papillae from seven human donors and cloned the cells in tissue culture; no additional growth factors were added to the cultures. After a few days, the cultured papillae were transplanted between the dermis and epidermis of human skin that had been grafted onto the backs of mice. In five of the seven tests, the transplants resulted in new hair growth that lasted at least six weeks. DNA analysis confirmed that the new hair follicles were human and genetically matched the donors.

“This approach has the potential to transform the medical treatment of hair loss,” said Dr. Christiano. “Current hair-loss medications tend to slow the loss of hair follicles or potentially stimulate the growth of existing hairs, but they do not create new hair follicles. Neither do conventional hair transplants, which relocate a set number of hairs from the back of the scalp to the front. Our method, in contrast, has the potential to actually grow new follicles using a patient’s own cells. This could greatly expand the utility of hair restoration surgery to women and to younger patients—now it is largely restricted to the treatment of male-pattern baldness in patients with stable disease.”

More work needs to be done before the method can be tested in humans, according to the researchers. “We need to establish the origins of the critical intrinsic properties of the newly induced hairs, such as their hair cycle kinetics, color, angle, positioning, and texture” said Dr. Jahoda. “We also need to establish the role of the host epidermal cells that the dermal papilla cells interact with, to make the new structures.”  The team is optimistic that clinical trials could begin in the near future. “We also think that this study is an important step toward the goal of creating a replacement skin that contains hair follicles for use with, for example, burn patients,” said Dr Jahoda.

The researchers used gene expression analyses to determine that the three-dimensional cultures restored 22 percent of the gene expression seen in normal hair follicles. “That’s less than we expected, but it was sufficient for inducing the growth of new hair follicles,” said Dr. Christiano.

In addition, using methods for the analysis of regulatory networks developed by the Califano lab in the Center for Computational Biology and Bioinformatics, Department of Systems Biology, the researchers identified a number of transcription factors (gene regulators) that have the potential to mimic the environmental signals that trigger papillae to induce new hair growth. This information could help researchers develop ways to restore the expression of more genes involved in hair growth and to increase the efficiency of the induction.

The paper is titled, “Microenvironmental reprogramming by three-dimensional culture enables dermal papilla cells to induce de novo human hair follicle growth.” The other contributors are James C. Chen and Jane E. Cerise, both at CUMC.

The study was supported by a Science of Human Appearance Career Development Award from the Dermatology Foundation and by grants from the Medical Research Council of the UK, the Empire State Development’s Division of Science, Technology and Innovation (NYSTAR), New York Stem Cell Science (NYSTEM), and the Biotechnology and Biological Sciences Research Council in the UK (BBSRC), as well as earlier support from the Steven and Michele Kirsch Foundation. Dr. Christiano is a member of the Columbia Stem Cell Initiative. The authors declare no financial or other conflicts of interests.

Source: Newsroom.columbia.edu


Chinese vaccine to save Asian children from encephalitis gets WHO nod

China’s first vaccine to save children in Asia from deadly Japanese encephalitis has been approved for global use by the World Health Organization.

The vaccine, manufactured by the Chengdu Institute of Biological Products, has received WHO prequalification, which means it meets international standards for quality, safety and efficacy.

According to China Daily, WHO Director-General Margaret Chan said that the move from China, which is producing vaccines up to WHO standards, is a welcome development, both in the fight to protect children in developing countries from the virus and in the future availability of vaccines more generally.

She said that there is a huge potential for vaccine manufacture in China, adding that she hopes to see more Chinese vaccines get WHO prequalification. The whole world will benefit.

The GAVI Alliance, a public-private global health partnership committed to saving children and increasing access to immunization in poor countries, said it is preparing to make funding available for the vaccine, the report said.

CEO Seth Berkley said that the Chinese vaccine industry has huge potential to benefit children in the poorest countries by offering secure, predictable supply at affordable prices, the report added.

The GAVI Alliance brings together governments, the WHO, UNICEF, the World Bank, vaccine industries in industrialized and developing countries, research and technical agencies and civil societies and the Bill and Melinda Gates Foundation and other private philanthropists.

Japanese encephalitis is a vicious illness that strikes quickly and usually has a devastating impact on children and their families, Berkley said.

Source: http://bit.ly/HGM7S2